1. Pain Freedom at 2‐8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response. Issue 10 (29th November 2020) Authors: L'Italien, Gilbert J.; Croop, Robert; Stock, David A. Journal: Headache Issue: Volume 60:Issue 10(2020) Page Start: 2611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Issue 7 (19th March 2022) Authors: Bhardwaj, Rajinder; Collins, Julie L.; Stringfellow, Joseph; Madonia, Jennifer; Anderson, Matt S.; Finley, Jeri‐anne; Stock, David A.; Coric, Vladimir; Croop, Robert; Bertz, Richard Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 7(2022) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir. (1st March 2018) Authors: Lataillade, Max; Zhou, Nannan; Joshi, Samit R.; Lee, Sangil; Stock, David A.; Hanna, George J.; Krystal, Mark Journal: Journal of acquired immune deficiency syndromes Issue: Volume 77:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Issue 9 (14th October 2022) Authors: Croop, Robert; Madonia, Jennifer; Stock, David A.; Thiry, Alexandra; Forshaw, Micaela; Murphy, Abigail; Coric, Vladimir; Lipton, Richard B. Journal: Headache Issue: Volume 62:Issue 9(2022) Page Start: 1153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗